<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04187443</url>
  </required_header>
  <id_info>
    <org_study_id>2019-001-CN</org_study_id>
    <nct_id>NCT04187443</nct_id>
  </id_info>
  <brief_title>MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema</brief_title>
  <official_title>A Multicenter, Open-label, Dose Escalation Study Assessing the Safety and Treatment Effects of MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fountain Medical Development Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MingSight Pharmaceuticals Pty Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label dose-escalation study to evaluate the safety and treatment benefits of
      MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema.
      Fifteen subjects with diabetic macular edema will be enrolled into each of three dose cohorts
      and will receive oral administration of MS-553 for 8 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Anticipated">October 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 18, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>Baseline to Day 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in the central retina subfield thickness (CRT)</measure>
    <time_frame>Baseline to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in the retinal volume</measure>
    <time_frame>Baseline to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with &gt;20% reduction in CRT</measure>
    <time_frame>Baseline to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with resolution of central involved macular edema</measure>
    <time_frame>Baseline to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average mean change in best corrected visual acuity</measure>
    <time_frame>Baseline to Day 56</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Macular Edema</condition>
  <condition>Type 2 Diabetes With Diabetic Macular Edema</condition>
  <condition>Type 1 Diabetes With Diabetic Macular Edema</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>MS-553 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose of MS-553 taken orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MS-553 mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mid dose of MS-553 taken orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MS-553 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose of MS-553 taken orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MS-553</intervention_name>
    <description>MS-553</description>
    <arm_group_label>MS-553 high dose</arm_group_label>
    <arm_group_label>MS-553 low dose</arm_group_label>
    <arm_group_label>MS-553 mid dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of diabetes mellitus (type 1 or type 2) according to ADA or WHO diabetic
             diagnosis criteria

          -  Subject has the ability to follow the study instructions and is likely to complete all
             required study procedures and visits;

          -  All males and females must consent to pregnancy prevention during the study and
             qualified measures of birth control. All females of childbearing potential must
             consent to a pregnancy test before entering the study.

          -  Presence of central involved macular edema associated with diabetic retinopathy, i.e.
             diabetic macular edema (DME), as assessed by spectral domain optical coherence
             tomography (sd-OCT) of the central retina subfield thickness (CRT) at the Screening
             Visit (Centration must be confirmed by Investigators with signatures);

          -  Best Corrected Visual Acuity (BCVA) score â‰¥ 34 letters (approximately 20/200 to 20/20
             Snellen equivalent or better) using the Early Treatment Diabetic Retinopathy Study
             (ETDRS) visual acuity protocol, and assessed at the Screening Visit Visual acuity
             (VA);

          -  Confirmation by the investigator that laser photocoagulation and anti-VEGF treatments
             are either declined by the patients or not needed and can be withheld for at least 3
             months after the Screening Visit;

          -  Ocular media and pupil dilation adequate to permit good quality retinal imaging as
             assessed at Screening Visit.

        Exclusion Criteria:

          -  Subjects with unstable metabolic or blood pressure control

          -  Subject with emaciation or obesity at Screening Visit: body mass index (BMI)
             &lt;18.5kg/m2 or &gt;28kg/m2

          -  Current use or likely need for medications know to be toxic to the lens, retina or
             optic nerve, including Deferoxamine, Chloroquine / hydroxychloroquine (Plaquenil),
             Tamoxifen, Phenothiazines and Ethambutol -

          -  History of myocardial infarction or other cardiac event requiring hospitalization
             (unstable angina pectoris, etc.), cerebrovascular accident, transient ischemic attack,
             treatment for acute congestive heart failure or any arrhythmia within 4-months prior
             to Screening Visit;

          -  Any situation that may in the opinion of the investigator preclude the safe
             administration of the study medication, adherence to the scheduled study visits, safe
             participation in the study or affect the results of the study as assessed at Screening
             Visit;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Zhang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ling Yang</last_name>
    <phone>+8613421382136</phone>
    <email>yangling@relin.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xun Xu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kun Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Macular Edema</keyword>
  <keyword>Macular Edema</keyword>
  <keyword>Center-involved Diabetic Macular Edema</keyword>
  <keyword>Center-involved DME</keyword>
  <keyword>DME</keyword>
  <keyword>Diabetic Retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

